Genomic analysis of Klebsiella pneumoniae ST258 strain coproducing KPC-2 and CTX-M-14 isolated from poultry in the Brazilian Amazon Region
Valiatti, Tiago Barcelos; Cayô, Rodrigo; Santos, Fernanda Fernandes; Bessa Neto, Francisco Ozório; Silva, Ramon Giovani Brandão; Veiga, Ruanita; Bahia, Márcia de Nazaré Miranda; Guerra, Lívia Maria Guimarães Dutra; Pignatari, Antônio Carlos Campos; Souza, Cintya de Oliveira; Brasiliense, Danielle Muruci; Gales, Ana Cristina.
VALIATTI, Tiago Barcelos et al. Genomic analysis of Klebsiella pneumoniae ST258 strain coproducing KPC-2 and CTX-M-14 isolated from poultry in the Brazilian Amazon Region. Antibiotics, v. 11, n. 12, Dec. 2022. DOI: https://doi.org/10.3390/antibiotics11121835. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774611/pdf/antibiotics-11-01835.pdf.
Artigo
em Inglês
| Instituto Evandro Chagas (DSpace) | ID: ied-6711
This study aimed to characterize a Klebsiella pneumoniae strain (KP411) recovered from the stool samples of poultry (Gallus gallus) in the Brazilian Amazon Region. The whole-genome sequencing of KP411 revealed the presence of an important arsenal of antimicrobial resistance genes to ß-lactams (blaCTX-M-14, blaTEM-1B, blaKPC-2, blaSVH-11), aminoglycosides [aph(300)- Ib, aph(6)-Id, aph(30)-Ia], sulfonamides (sul1, sul2), quinolones (oqxAB), fosfomycin (fosAKP), and macrolides [mph(A)]. Furthermore, our analyses revealed that the KP411 strain belongs to the ST258 clonal lineage, which is one of the main epidemic clones responsible for the dissemination of KPC-2 worldwide. Our data suggest that food-producing animals may act as reservoirs of multidrug-resistant K. pneumoniae belonging to the ST258 clone, and, consequently, contribute to their dissemination to humans and the environment. / National Council for Science and Technological Development (CNPq) and the Bill & Melinda Gates Foundation (process numbers 402659/2018-0, 443805/2018-0, and OPP1193112); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for providing grants to TBV, RGBS, FFS (PNPD), and to the CNPq for providing grants to FOB-N, RFB-N., RV, and ACG (process number 312066/2019-8). A.C.G. has recently received research funding and/or consultation fees from bioMérieux, Eurofarma, MSD, Pfizer, Roche, Sandoz, and United Medical. This study was not financially supported by any diagnostic/pharmaceutical company
Texto completo
Documentos relacionados